ALK-Abelló A/S

Copenhagen Stock Exchange ALK-B.CO

ALK-Abelló A/S Net Cash Used For Investing Activities for the year ending December 31, 2023: USD -55.51 M

ALK-Abelló A/S Net Cash Used For Investing Activities is USD -55.51 M for the year ending December 31, 2023, a -10.20% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

ALK-Abelló A/S Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -50.37 M, a -23.89% change year over year.
ALK-Abelló A/S Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -40.66 M, a -1.31% change year over year.
ALK-Abelló A/S Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD -40.13 M, a -70.75% change year over year.
ALK-Abelló A/S Net Cash Used For Investing Activities for the year ending December 31, 2019 was USD -23.50 M, a 23.11% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

Copenhagen Stock Exchange: ALK-B.CO

ALK-Abelló A/S

CEO	Mr. Peter Halling
IPO Date	March 10, 2000
Location	Denmark
Headquarters	Boge Alle 6-8
Employees	2,806
Sector	Consumers Staples
Industries Personal Care Biotechnology Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Pet Food Pharmaceuticals Pollution Treatment

Description

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.

Key trends

Past 5 years